Document is current
Any future updates will be listed below
-
Authors
Safarika, Asimina
Wacker, James W.
Katsaros, Konstantinos
Solomonidi, Nicky
Giannikopoulos, George
Kotsaki, Antigone
Koutelidakis, Ioannis M.
Coyle, Sabrina M.
Cheng, Henry K.
Liesenfeld, Oliver
Sweeney, Timothy E.
Giamarellos-Bourboulis, Evangelos J. http://orcid.org/0000-0003-4713-3911
-
Funding
Funding for this research was provided by:
Inflammatix Inc Clinical Affairs
- License Information
-
More Information
Article History
Received: 10 December 2020
Accepted: 12 May 2021
First Online: 18 June 2021
Declarations
:
: The PROMPT study was conducted under the approvals EBD2392/16.05.2017 of ATTIKON University General Hospital; 7/26.05.2017 of the General Hospital of Sparti; 1/20.07.2017 of the General Hospital of Syros; 8/12.07.2017 of the General Hospital of Halkida; 42550/20.10.2017 of the General Hospital of Argos; and 4/31.05.2017 of “G. Gennimatas” General Hospital of Thessaloniki.
: Does not apply.
: James W. Wacker, Sabrina M. Coyle, Henry K. Cheng, Oliver Liesenfeld, and Timothy E. Sweeney are employees of, and shareholders in Inflammatix. The other authors have no conflicts of interest to declare. E.J. Giamarellos-Bourboulis has received honoraria from Abbott CH, Angelini Italy, InflaRx GmbH, MSD Greece, XBiotech Inc., and B·R·A·H·M·S GmbH (Thermo Fisher Scientific); independent educational grants from AbbVie Inc, Abbott CH, Astellas Pharma Europe, AxisShield, bioMérieux Inc, Novartis, InflaRx GmbH, Swedish Orphan BioVitrum AB and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis).
